Endomyocardial biopsies from 237 patients with virus-negative inflammatory cardiomyopathy treated with immunosuppression were retrospectively examined for the expression of TLR4, differentiating those patients responding to immunosuppression (n = 193) from non-responder patients (n = 44). A semiquantitative evaluation of the immunoreactivity (grading from 0 to 4) for TLR4 and human leucocyte antigen (HLA)-DR was performed together with real-time PCR and western blot for TLR4. Cardiomyocyte apoptosis and necrosis was evaluated by in situ ligation with hairpin probes. A focal intense positive cytoplasmic immunostaining for TLR4 was observed in cardiomyocytes of all responders (P < 0.001 vs. non-responders). A grading 2 or above (2+) at baseline showed a sensitivity of 100% and 90.9% specificity with a positive predictive value of 98% as a predictor of an immunosuppression-positive response. Real-time PCR and western blot analysis for TLR4 were 4.3-fold and 4.6-fold higher, respectively, in responders vs. non-responders. Correlation between TLR4 grading and TLR4 mRNA molecular and protein expression was highly significant. HLA-DR did not discriminate between the two groups. Cardiomyocyte death by apoptosis was 3.7-fold higher in responders vs. non-responders and significantly correlated with TLR4
Introduction
Myocarditis is an inflammatory disease of the heart frequently resulting from viral infections and/or post-viral immune-mediated responses.
1 Although in about 40% of cases acute myocarditis may resolve spontaneously, in the remaining patients it evolves to a chronic phase with ventricular dilation, reduced contractility, and clinical progression to heart failure. A specific standardized treatment is not yet available and the strategies used are those usually adopted for the management of heart failure.
Non-randomized studies 2, 3 and a recent randomized trial 4 showed that patients with myocarditis and chronic heart failure with negative cardiac polymerase chain reaction (PCR) for the main cardiotropic viruses, so-called virus-negative patients, may benefit from immunosuppressive treatment, suggesting a prevalent immune-mediated mechanism of damage. Nevertheless, among them some patients showed a significant improvement of cardiac dimension and function with recovery of a normal cardiac performance, while others not distinguishable from the previous ones, failed to respond. 4 This uncertain response to treatment makes the use of immunosuppression still debated. On the other hand, the actually available biomarkers as circulating cardiac autoantibodies and tissue expression of human leucocyte antigen (HLA)-DR are of limited discriminative value.
Thus, it appears desirable to identify biological markers able to predict the response to immunosuppression in patients potentially candidate to immunosuppressive therapy. Several experimental and human studies have suggested a potential role of Toll-like receptors (TLRs), molecular components that regulate the innate immune system, in the induction and perpetuation of inflammation in autoimmune diseases. 5 -7 Specifically, the cell surface Toll-like receptor 4 (TLR4) has been implicated in the development of several experimental and human autoimmune disorders, including experimental autoimmune encephalomyelitis, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, type 1 diabetes, and multiple sclerosis. 8 -11 In the heart TLR4 binds to endogenous ligand following cardiac injury and is an important mediator of the inflammatory reactions implicated in myocardial ischaemia/reperfusion injury, 12 septic cardiomyopathy, 13 maladaptive remodelling, 14 increased infarct size, and reduced survival after myocardial infarction. 15 Moreover, TLR4 has been demonstrated to be essential for the induction of experimental autoimmune myocarditis by cardiac myosin. 16 -18 On the basis of this evidence, the aim of this study was to evaluate the role of TLR4 in human virus-negative inflammatory cardiomyopathy and to determine whether TLR4 expression is able to predict the response to immunosuppressive therapy in this group of patients.
Methods

Patient population
At our Institution, between January 2009 and January 2016, 403 patients underwent an endomyocardial biopsy because of idiopathic left ventricular (LV) dysfunction [LV ejection fraction (LVEF) ≤ 45%]. A diagnosis of inflammatory cardiomyopathy was made in 336 of the patients on the basis of the current definition 1 and among those, 237 patients were diagnosed as affected by virus-negative chronic inflammatory cardiomyopathy on the basis of : (i) clinical signs and symptoms of heart failure lasting >6 months despite optimal supportive therapy with ACE-inhibitors, diuretics, carvedilol, digitalis; (ii) instrumental evidence of left or biventricular dilation and dysfunction (LVEF ≤ 45%); (iii) histological and immunohistochemical diagnosis of chronic active lymphocytic myocarditis (myocarditis with increased fibrosis and focal cardiomyocyte necrosis); (iv) absence of cardiotropic viral genomes at PCR in at least two frozen samples; (v) The inclusion criteria of patients enrolled in the present study were those used for the Tailored Immunosuppression in Inflammatory Cardiomyopathy (TIMIC) trial, where the efficacy of immunosuppressive therapy has been demonstrated. 4 On the basis of the TIMIC trial results, 4 all patients were submitted to an immunosuppressive treatment including 1 mg/kg prednisone daily for 4 weeks followed by 0.33 mg/kg daily for 5 months, and 2 mg/kg azathioprine daily for 6 months.
The study was approved by the local Ethics Committee and patients gave their informed consent.
Clinical criteria of response to immunosuppressive therapy were applied at the end of treatment. Patients were defined as responders if they showed an improvement of cardiac function and dimensions, defined as an increase of >10 percentage points in the absolute LVEF and a reduction of LV end-diastolic volume (LVEDV) or LV end-diastolic diameter (LVEDD) ≥10%, and non-responders if there was either a mild but not significant improvement (<10%) or unchanged or worsened cardiac parameters. Among the 237 patients, 193 (81%) were responders and 44 (19%) were non-responders.
Endomyocardial samples from all patients were retrospectively studied with immunohistochemical, real-time PCR and western blot analysis for TLR4.
As normal controls, LV surgical biopsies from 30 patients (12 male/18 female, median age 48 years, interquartile range: 39-56 years) with mitral stenosis and normal LV dimension and function, undergoing surgical valve replacement, were used in all the assays. These endomyocardial fragments, although not obtained from healthy individuals, derived from a not overloaded chamber and were considered the nearest samples to a normal endomyocardial tissue. 19 
Clinical studies
Clinical assessment, resting electrocardiogram, Holter monitoring, and 2D-echocardiography were performed at baseline in all patients. Cardiac catheterization, angiography, and left or biventricular endomyocardial biopsy were also performed, after patients had given informed consent. The New York Heart Association (NYHA) classification was used to assess functional capacity determined by means of a questionnaire. Echocardiographic parameters were determined according to established criteria. 4 Cardiac magnetic resonance imaging (MRI) with late gadolinium enhancement was performed in only 52% of cases. Functional and morphological data were analysed according to the Lake Louise criteria.
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Endomyocardial biopsy studies
Endomyocardial biopsies (3-4 from each ventricular chamber) were performed in the septal-apical region of left or both ventricles. 19 Samples were either fixed in formalin and paraffin-embedded for histopathology and immunohistochemistry or snap frozen for molecular biology and western blot analysis. For the phenotypic characterization of the inflammatory infiltrates, immunohistochemistry for Cluster of Differentiation (CD)3, CD20, CD43, CD45RO, and CD68 was performed (all Dako, Carpinteria, CA, USA). The presence of an inflammatory infiltrate ≥14 leucocytes/mm 2 including up to 4 monocytes/mm 2 , with the presence of CD3-positive T-lymphocytes ≥7 cells/mm 2 associated with evidence of degeneration and/or necrosis of the adjacent cardiomyocytes, was considered diagnostic for myocarditis. 1 The number of CD3-positive cells was manually counted using a tally counter on high power field (×400) scanning the entire slide. The area of tissue samples was measured by means of a computerized system (Imaging Software/NIS-Elements AR 4.30, Nikon Instruments Inc., Melville, NY, USA). The number of CD3-positive cells was expressed as number of cells per square millimetre. Morphometric evaluation was performed by a pathologist blinded to clinical data.
For the assessment of TLR4 expression, myocardial sections were incubated with a mouse monoclonal TLR4 antibody 1:10 dilution (HTA125, Santa Cruz Biotechnology Inc., Dallas, TX, USA), and a peroxidase/anti-peroxidase complex, followed by labelling with the chromogen diaminobenzidine (Dako). Immunohistochemistry for HLA-DR (Dako) was also performed as described. 4 A semiquantitative evaluation of the cytoplasmic immunoreactivity for TLR4 and HLA-DR (grading from 0 to 4) was applied. For TLR4 grade 0 was attributed to absence of immunostaining, grade 1 to 1-10% positive cardiomyocytes, grade 2 to 11-30%, grade 3 to 31-60% and grade 4 to >60% positivity. Appropriate positive and negative controls were used, including sections of giant cell myocarditis (positive control), and tissues incubated with antibody diluent, without the primary antibody, followed by incubation with secondary antibodies and detection reagents (negative control). In addition, samples were incubated with antibody diluent, supplemented with a non-immune immunoglobulin of the same isotype (IgG2a) and concentration as the primary monoclonal antibody. The samples were then incubated with the secondary antibody and detection reagents. These steps were adopted to rule out that what appears to be specific staining was not caused by non-specific interactions of immunoglobulin molecules with the samples.
In situ ligation of hairpin probes with single-base 3 ′ overhangs or blunt ends were used to measure cardiomyocyte apoptosis (hairpin 1) and necrosis (hairpin 2), respectively. 21 Cardiomyocytes were detected by means of alpha sarcomeric actin antibody (clone 5C5, Sigma, St. Louis, MO, USA).
The immunohistological examination of biopsy specimens was made by two investigators independently; each was blinded to clinical features and histopathological diagnosis.
Molecular biology studies
In all patients at baseline a PCR for the most common cardiotropic viruses (adenovirus, enterovirus, influenza A and B viruses, Epstein-Barr virus, Parvovirus B19, Hepatitis C virus, Cytomegalovirus, Human Herpes Virus 6, Herpes Simplex virus A and B) was performed to exclude a myocardial viral infection.
For TLR4 real-time PCR, RNA was extracted with a commercial kit (Qiagen) according to the manufacturer's instructions. The housekeeping gene GAPDH was used for normalizing PCR data. Real-time PCR reactions were performed with a CFX-96 thermal cycler (BD, Bioscience Clontech, Palo Alto, CA, USA). Primer sets for all amplicons were designed using the Primer-Express 1.0 software system as listed below.
TLR4 forward:
Protein analysis
Western blot analysis was performed using a monoclonal antibody against human TLR4 specific for western blot (76B357. 
Follow-up
All patients were followed-up weekly in the first month and every 4 weeks in the remaining 5 months of treatment with clinical assessment and with non-invasive cardiac studies. All patients also received a control endomyocardial biopsy at the end of treatment.
Statistical analysis
Data are presented as counts and percentage for categorical variables, while for numeric variables, median and interquartile range are shown.
Comparison among groups (responders vs. non-responders or eventually controls) was performed using the Mann-Whitney U-test for numeric and the 2 test (or Fisher where applicable) for categorical variables. A value of P < 0.05 was considered as significant. The correlations between TLR4 grading and TLR4 real-time PCR values and western blot densitometry results were explored with Spearman's correlation as well as the correlation between delta (Δ) of ejection fraction (considering values at baseline and at the end of treatment) with TLR4 grading. Pre-and post-treatment data were compared using the paired Wilcoxon test. The validity of the TLR4 (using all three methods of evaluation) as a predictor of response after treatment was assessed by plotting receiver-operating characteristic (ROC) curves and area under the curve (AUC) was calculated. Data management and analysis was performed using SPSS version 23 (IBM, USA).
Results
A comparison of baseline clinical, morphometric and histochemical parameters between responders and non-responders is presented in Table 1 .
Clinical studies
No differences were registered in terms of age, time to onset of symptoms, severity of dyspnoea and degree of LV dilation/dysfunction between responders and non-responders. Responders were more likely to be women (P = 0.003) and this is consistent with the prevalence of autoimmune disorders in females compared with males. Coronary arteries were normal in all patients. At cardiac MRI the Lake Louise criteria were met in 38% of the 123 cases in which MRI was performed, with no differences among responder and non-responder patients.
Endomyocardial biopsy studies
Responders and non-responders were not distinguishable at baseline from a histological point of view since in both a focally active myocarditis with lymphomononuclear infiltrates and necrosis of the adjacent cardiomyocytes was evident ( Figure 1A and B, Table 1 ). Extent of fibrosis was comparable as well as intensity of T-lymphocyte inflammatory infiltrates ( Table 1) . Semiquantitative evaluation of immunostaining (grades from 0 to 4) for TLR4 showed an increased cardiomyocyte expression of TLR4 in responders compared with non-responder patients (P < 0.001) as well as with controls (control values median 0) ( Figures 1C and D, and 2A) . Expression of TLR4 at baseline (according to all three methods of measurement) was higher in females compared with males (P < 0.005) overall but this difference was observed only among responders, while no difference emerged in non-responders. Grading 2 or above (2+) at baseline showed a sensitivity of 100%, a specificity of 90.9%, with a positive predictive value (PPV) of 98% and a negative predictive value (NPV) of 100% for a positive response to immunosuppressive therapy ( Figure 1E and F, Table 1 , vs. normal controls: P < 0.001).
The degree of necrotic cardiomyocyte cell death was comparable between responders and non-responders (median value 1789 vs. 1896 × 10 6 cells), significantly higher than in controls (median normal value = 146 × 10 6 cells, P < 0.001). Cardiomyocyte death by apoptosis was more prevalent in responders (median value 3897 cells) than in non-responders (median value 1056 cells, P < 0.001) ( Table 1) , and significantly higher than in controls (median normal values = 18/10 6 cells, P < 0.001) (Figure 3 ).
Molecular biology studies
The relative quantitative analysis showed that the median TLR4 mRNA expression was 4.3-fold higher in responders compared with non-responders (P < 0.001) ( Figure 2B , Table 1 
Protein studies
Protein analysis showed a 4.6-fold increase in median TLR4 protein expression in responders compared with non-responders and an almost 21-fold increase when compared with controls ( Figure 2C and D, Table 1 ) (P < 0.001).
Correlation
The correlation between TLR4 grading and TLR4 molecular and protein expression was highly significant (Spearman's rank correlation of 0.920 and 0.898, respectively (Figure 3) . In all patients, a correlation was found between TLR4 grading, mRNA and protein expression at baseline, and the variation (Δ) of LVEF before and after treatment (Spearman's 0.8603, 0.7334 and 0.6230) ( Figure 4E ).
ROC analysis
ROC analysis was performed to test the reliability of the different measurements of TLR4 as predictors of a good response to immunosuppressive treatment. All three measurements were found to be good predictors with an area under the curve always exceeding 99.5%. Optimal cut-off values were 2 for grading (sensitivity 100%, specificity 90.9%, Table 2 ), 0.8 for molecular (sensitivity 99.0% and specificity 88.6%) and 24 000 for protein expression (sensitivity 100%, specificity 95.5%).
Follow-up
All responders showed a significant reduction in LVEDD (median value from 68 to 54 mm, P < 0.001), LVEDV (from 245 to 145 mL, P < 0.001); LV end-systolic volume (LVESV; from 178.6 to 72.9 mL, P < 0.001), and an increase in LVEF (from 25 to 50%, P < 0.001) after 6 months of immunosuppression. Non-responders showed an overall mild (LVEDD from 67.5 to 66 mm, P = 0.021; LVESV from 185.6 to 181.9 mL, P < 0.001; LVEF from 25 to 27%, P < 0.001) or no significant improvement (LVEDV from 247.5 to 245 mL, P = 0.697). In responders the control endomyocardial biopsy showed a disappearance of inflammatory infiltrates and a significant (Figure 4A-D) . In non-responders, myocardial inflammation was reduced or disappeared in the control biopsies but some degenerative changes of cardiomyocytes were observed. Control real-time PCR and western blot analysis of TLR4 expression in responders showed a significant reduction compared with baseline biopsies (real-time PCR from 1.30 to 0, P < 0.001; western blot from 43 748 to 3547, P < 0.001). In non-responders the TLR4 values appeared substantially unmodified or slightly reduced (grading from 1 to 1, P = 0.157; real-time PCR from 0.3 to 0.2, P = 0.166; western blot from 9563 to 8478, P = 0.082).
Discussion
Most patients with chronic inflammatory cardiomyopathy are characterized by the absence of viral genomes in the myocardium 22 . These patients, often with several months or even years of clinical history, are usually treated with the maximal tolerated dosage of supportive therapy, including ACE-inhibitors, diuretics, carvedilol, digitalis. However, in the presence of still active cell damage and progressive muscle impairment, they could benefit from a specific treatment able to counteract the mechanisms responsible for persisting cardiomyocyte inflammation and death.
Other groups and ours have demonstrated that treatment with steroids and immunosuppressive drugs 2 -4,23 may improve and often normalize cardiac function in this group of patients, even in the presence of a long-lasting history and a severe degree of heart failure. However, immunosuppressive therapy is not yet universally accepted because of the absence of multicentre randomized controlled trials and also the evidence of a cohort who fails to respond. The absence of viral genomes in the myocardium seems to be not enough to predict a successful response to this treatment, asking for the identification of new reliable biomarkers. Our study showed that myocardial TLR4 expression is a tissue marker able to discriminate, among virus-negative patients with chronic inflammatory cardiomyopathy, those who can benefit from immunosuppressive therapy.
Toll-like receptor 4 expression in autoimmune inflammatory cardiomyopathy
The innate immune system plays an important role in the pathogenesis and evolution of myocarditis. TLRs are key molecular components of the innate immune response and play a crucial role in the activation of adaptive immunity. 24 A family of at least 13 TLRs has emerged that can recognize the conserved molecular patterns of all microbial classes, so-called pathogen-associated molecular patterns, and protect the host from these pathogens. However, TLR ligand selectivity is relatively low, and TLRs also recognize self-molecules generated during tissue damage and inflammation, the so-called damage-associated molecular patterns. In autoimmune diseases, upon activation, TLRs initiate the downstream intracellular signalling leading to aberrant stimulation and unrestricted inflammatory reaction, thereby contributing to the initiation and perpetuation of the inflammatory response. TLR4 in particular has been linked to autoimmune inflammation. Naïve T cells stimulated through the TLR4 pathway did proliferate more extensively and exhibited enhanced survival, while in the absence of TLR4 signalling, T cells are unable to survive or reactivate, leading to a reduction in autoimmune-associated inflammation. 5 In experimental autoimmune myocarditis induced by myosin, the TLR4-triggered Th1 immune response was required for the development of myocardial inflammation. 25 In TLR4 knock-out mice immunized with myosin, a decreased myocardial inflammatory infiltration compared with wild type mice was seen, associated with reduced production of IFN-and IL-2 and with inhibition of TLR4-induced NF-B activation and signalling. 18 Similarly, adiponectin is able to attenuate myocardial inflammation and injury in experimental autoimmune myocarditis, interfering with TLR4 signalling in immune cells and inhibiting the expression of a TLR4-mediated inflammatory phenotype in cardiomyocytes. 26 Our study showed that TLR4 is highly expressed in the cardiomyocyte cytoplasm of a subgroup of patients with chronic virus-negative inflammatory cardiomyopathy responding to immunosuppressive therapy. In these patients the high level of TLR4 was confirmed at mRNA and protein levels, and significantly differed from normal controls and from patients with myocarditis not responding to immunosuppression. Thus, TLR4 overexpression in human myocarditis is highly suggestive of an autoimmune operating mechanism of cardiomyocyte damage and death.
Additionally, TLR4-mediated activation of cardiac inflammatory signalling has been found to be associated with the induction of apoptosis. Indeed, in doxorubicin cardiomyopathy TLR4 knock-out mice showed a significantly attenuated proapoptotic protein Bax and a reduction in terminal deoxynucleotidyl-transferase-mediated dUTP nick end-labeling assay for the detection of apoptotic nuclei (TUNEL)-positive cardiomyocytes compared with wild type mice, associated with an increase in B-cell lymphoma 2 (Bcl-2) suggesting antiapoptotic protection due to TLR4 deficiency. 27 The TLR4-NF-B pathway has been involved in myocyte apoptosis in failing ischaemic myocardium.
28 TLR4 is also crucial in inducing cardiomyocyte apoptosis in acute myocardial infarction, where the extent of apoptosis and Bax/Bcl-2 ratio was strongly correlated with TLR4 levels. 29 In our study, responders had 3.3-fold higher levels of apoptosis compared with non-responders and TLR4 expression positively correlated with the amount of cardiomyocyte apoptosis. Apoptosis represents the prevalent mechanism of cell death in responders, while necrosis was lower and comparable to non-responders. This last evidence is most likely related to the similar degree of focal T cellular infiltration with degeneration of the adjacent myocytes, while TLR4-mediated apoptosis could be one of the mechanisms responsible for cardiac dysfunction of responders.
Toll-like receptor 4 and response to immunosuppressive therapy
Our study showed that myocardial expression of TLR4 is able to differentiate among virus-negative patients with chronic . inflammatory cardiomyopathy the responders to immunosuppressive treatment. In particular, all three measurements proved to be good predictors. Optimal cut-off values were 2 for grading (sensitivity 100%, specificity 90.9%), 0.8 for molecular (sensitivity 99.0% and specificity 88.6%) and 24 000 for protein expression (sensitivity 100%, specificity 95.5%), indicating TLR4 as an easy and sensitive marker of autoimmune myocarditis. Expression of TLR4 at baseline was higher in females compared with males and responders were more likely to be women, and this is consistent with the prevalence of autoimmune disorders in females compared with males.
When comparing TLR4 with myocardial expression of HLA-DR, already adopted as a possible marker of autoimmune myocarditis, 30 our results showed that it was similarly expressed in the two groups. Indeed, it has been shown that HLA-DR expression on the cardiomyocyte surface is present in up to 60% of patients with idiopathic heart failure independently of the presence of myocarditis, 29 and in the setting of an inflammatory cardiomyopathy, HLA-DR expression, especially in the area of inflammatory cell infiltration, basically indicates the activation of the immune system. Thus, in our experience, HLA-DR seems not to be a tissue marker specific for autoimmune myocarditis.
When compared with the clinical response to treatment, TLR4 showed a linear positive correlation with the variation in LVEF from baseline to 6 months of immunosuppression. In addition, in control biopsies, the disappearance of inflammatory infiltrates was paralleled by a significant reduction in TLR4 expression.
In non-responder patients, the low levels of myocardial TLR4 expression and the lack of response to immunosuppression delineate an inflammatory cardiomyopathy in which a mechanism different from autoimmunity was responsible for cardiac dysfunction, as for example the presence of still unknown viral agents.
The results of the present study refer to patients with non-viral inflammatory cardiomyopathy in a chronic stage and cannot be translated to all patients with virus-negative inflammatory cardiomyopathies.
Conclusions
TLR4 is highly expressed in human chronic non-viral myocarditis responding to immunosuppression. It can be considered as a new possible marker in patient selection for immunosuppressive therapy.
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